Effect of combined use of ivermectin and colchicine in COVID-19 patients

References

• University JH. Coronavirus resource center. 2022. Published 2020 [cited 2022 March 23]. Available from: https://coronavirus.jhu.edu/.
   Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine–Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341–350.
   PubMed Web of Science ®Google Scholar
• Pan P, Shen M, Yu Z, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun. 2021 Aug 2; 12(1):4664.
   Web of Science ®Google Scholar
• Bonaventura A, Vecchié A, Dagna L, et al. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res. 2022Mar;71(3):293–307. Epub 2022 Feb 3. PMID: 35113170; PMCID: PMC8811745.
   Web of Science ®Google Scholar
• Marques-da-Silva C, Chaves MM, Castro NG, et al. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol. 2011Jul;163(5):912–926. PMID: 21306580; PMCID: PMC3130939.
   PubMed Web of Science ®Google Scholar
• Bourguiba R, Delplanque M, Vinit C, et al. Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis. 2020 Nov 2; annrheumdis-2020-218707 doi:10.1136/annrheumdis-2020-218707. Epub ahead of print. PMID: 33139307
   Web of Science ®Google Scholar
• Pelechas E, Drossou V, Voulgari PV, et al. COVID-19 in patients with gout on colchicine. Rheumatol Int. 2021Aug;41(8):1503–1507. Epub 2021 Jun 5. PMID: 34089357; PMCID: PMC8178663.
   Web of Science ®Google Scholar
• Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021May;80(5):550–557. Epub 2020 Dec 8. PMID: 33293273; PMCID: PMC8491433.
   Web of Science ®Google Scholar
• Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856.
   PubMed Web of Science ®Google Scholar
• Sim¸sek Yavuz S, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI–1):611–619.
   PubMedGoogle Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;3:104787.
   Google Scholar
• Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021Apr22;28(3):e299–e318. Erratum in: Am J Ther. 2021 Nov-Dec 01;28(6):e813. PMID: 34375047; PMCID: PMC8088823.
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease. (COVID-19) treatment guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021 Apr 21 2022 Mar 24 2019. PMID: 34003615
   Google Scholar
• Marshall JC, Murthy S, Diaz J. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192–e197.
   PubMed Web of Science ®Google Scholar
• Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020Oct;79(10):1286–1289. Epub 2020 Jul 30. PMID: 32732245; PMCID: PMC7509521.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Bouabdallaoui N, L’Allier PL, et al. COLCORONA investigators. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021Aug;9(8):924–932. Epub 2021 May 27. PMID: 34051877; PMCID: PMC8159193.
   PubMed Web of Science ®Google Scholar
• Vrachatis DA, Giannopoulos GV, Giotaki SG, et al. Impact of colchicine on mortality in patients with COVID-19: a meta-analysis. Hellenic J Cardiol. 2021Sep-Oct;62(5):374–377. Epub 2021 Jan 6. PMID: 33421583; PMCID: PMC7833703.
   Web of Science ®Google Scholar
• Brunetti L, Diawara O, Tsai A, et al. Colchicine to weather the cytokine storm in hospitalized patients with COVID-19. J Clin Med. 2020 Sep 14; 9(9):2961.
   PubMed Web of Science ®Google Scholar
• Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021 Feb;7(1):e001455.
   PubMed Web of Science ®Google Scholar
• López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426–1435.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, et al. COL-COVID investigators. Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID). Int J Gen Med. 2021 Sep 11; 14:5517–5526
   Web of Science ®Google Scholar
• Lim SCL, Hor CP, Tay KH, et al. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial. JAMA Intern Med. cited 2022 Feb 18 182(4):426.
   Web of Science ®Google Scholar
• Karakaş Ö, Erden A, Güven SC, et al. Reducing length of hospital stay with colchicine. J Infect Dev Ctries. 2022 Jan 31; 16(1):57–62.
   Web of Science ®Google Scholar
• Karale S, Bansal V, Makadia J, et al. A meta-analysis of mortality, need for ICU admission, use of mechanical ventilation and adverse effects with ivermectin use in COVID-19 patients. medRxiv. 2021. preprint at. doi:10.1101/2021.04.30.21256415.
   Google Scholar
• Diaz R, Orlandini A, Castellana N, et al. ECLA PHRI COLCOVID trial investigators. effect of colchicine vs usual care alone on intubation and 28-Day mortality in patients hospitalized with COVID-19: a randomized clinical trial. JAMA Network Open. 2021 Dec 1; 4(12):e2141328.
   Web of Science ®Google Scholar
• Sandhu T, Tieng A, Chilimuri S, et al. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. Can J Infect Dis Med Microbiol. 2020;2020:8865954. Oct 27.
   Web of Science ®Google Scholar
• Reis G, Easm S, Silva DCM, et al. TOGETHER investigators. Effect of early treatment with ivermectin among patients with covid-19. N Engl J Med. 2022 Mar 30; 386(18):1721–1731.
   Google Scholar
• Chiu L, Lo CH, Shen M, et al. Colchicine use in patients with COVID-19: a systematic review and meta-analysis. PLoS One. 2021 Dec 28; 16(12):e0261358.
   Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021 Dec;9(12):1419–1426.
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study. J Med Virol. 2021Oct;93(10):5833–5838. Epub 2021 Jun 7. PMID: 34076901; PMCID: PMC8242425.
   PubMed Web of Science ®Google Scholar
• Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022 Dec;11(1):277–283.
   PubMed Web of Science ®Google Scholar